Quick Answer
Apimeds Pharmaceuticals US, Inc. reported Stockholders Equity of -$1.36 million for the year ending 2024.
- Apimeds Pharmaceuticals US, Inc. showed a decrease of -4,361.6% in Stockholders Equity from 2023 to 2024.
- This data is from Apimeds Pharmaceuticals US, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2022 to 2024 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2023: $31.9 thousand | Q1 2024: -$264.6 thousand | Q2 2024: -$714.0 thousand | Q3 2024: -$1.05 million | Q4 2024: -$1.36 million | Q1 2025: -$1.76 million | Q2 2025: $9.74 million | Q3 2025: $8.16 million.
- Over the full 3 years of available data (2022 to 2024), Apimeds Pharmaceuticals US, Inc.'s Stockholders Equity has declined by 90.3%.
- Historical annual values: Fiscal year 2024: -$1.36 million | Fiscal year 2023: $31.9 thousand | Fiscal year 2022: -$713.6 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: